Several radioimmunoconjugates have been approved for cancer diagnosis, for example,
arcitumomab (CEA-scan[R]), a [sup.99m]Tc-labeled antibody fragment used for imaging of colorectal cancer, and capromab pendetide (ProstaScint[R]), an 111 In-labeled mAb directed against prostate specific membrane antigen (PSMA) [78].
(25,26) These have included antibodies for imaging colorectal cancer (eg, satumomab pendetide, (27)
arcitumomab (24)), prostate cancer (eg, capromab pendetide (28-30)) NHL, (31) liver cancer, (32) myocardial infarcts (imciromab penlefate (33-35)), infection and inflammation (eg, sulesomab, fanolesomab (36-38)), specific infections, (2) and clots, (39) to mention a few that are now available or in development.